Keywords: BioAlliance Pharma, Sitavig, Orofacial herpes, USA, FDA, Registration dossier, NDA

BioAlliance's Sitavig NDA "receivable" by US FDA

Article | 30 May 2012

French biotech firm BioAlliance Pharma (Euronext Paris: BIO) has announced the receivability of its Sitavig ( (acyclovir Lauriad; European trade name ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

BioAlliance Pharma

Go to company listing

Related Drugs

Sitavig

Sitavir

Go to drug listing